Signatera™ for Gastroesophageal Cancer

Signatera™ is a tumor-informed MRD assay for gastroesophageal cancer, monitoring MRD from neoadjuvant therapy through post-surgical surveillance. Early MRD clearance during neoadjuvant therapy predicts favorable outcomes; persistent or post-surgical positivity is the strongest signal of recurrence risk — outperforming clinicopathologic staging and informing decisions about adjuvant therapy and surveillance intensity.

Order now

Inform clinical challenges in Gastroesophageal Cancer

Monitor neoadjuvant response

100%

overall survival in patients with early MRD clearance during neoadjuvant therapy.¹

Identify recurrence earlier

184

median days Signatera™ detects recurrence before imaging.¹

SGN_WB_MD_Gastroesophageal_20260210_NAT-8023503_TextImage1

Stratify recurrence risk beyond clinicopathologic staging

In the PLAGAST study (n=62), Signatera™ was tracked from neoadjuvant therapy through the post-surgical MRD window:

In the post-surgical window, Signatera™ positivity outperformed tumor stage, nodal status, and TRG score in predicting overall survival.¹

Early Signatera™ clearance identified patients with superior outcomes in gastroesophageal cancer¹

View details

SGN_WB_MD_Gastroesophageal_20260210_NAT-8023503_TextImage2

Signatera™-positivity during surveillance predicts recurrence in gastroesophageal cancer²

Signatera™ positivity during surveillance predicted recurrence with 95 % positive predictive value, while Signatera™ negativity had a 92 % negative predictive value in gastroesophageal cancer.²

Read the publication

Signatera™ informs clinical decisions across settings in gastroesophageal cancer

Is Signatera™ for Gastroesophageal cancer right for your patients?

First Name *

Last Name *

Email Address *

Phone *

Zip Code *

Country *

I am a *

Company

Comments

Natera Honey Pot

Natera would like to send you information about our products and services. You may unsubscribe from these communications at any time. By submitting your information you are agreeing to Natera's terms of use and privacy policy.

References

¹Zaanan A, Didelot A, Broudin C, et al. Longitudinal ctDNA analysis during treatment of resectable gastric and GEJ cancer: the PLAGAST study. Nature Communications. 2025;16:6815.

²Huffman BM, et al. Analysis of Circulating Tumor DNA to Predict Risk of Recurrence in Patients With Esophageal and Gastric Cancers. JCO Precision Oncology. 2022;6:e2200420.